CER - Central Repository
Institute of Chemistry, Technology and Metallurgy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   CER
  • IHTM
  • Radovi istraživača / Researchers' publications
  • View Item
  •   CER
  • IHTM
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Edaravone May Prevent Ferroptosis in ALS

Thumbnail
2020
2020_edaravon_sspasic.pdf (979.9Kb)
Authors
Spasić, Snežana
Nikolić-Kokić, Aleksandra
Miletić, Srđan
Oreščanin-Dušić, Zorana
Spasić, Mihajlo
Blagojević, Duško
Stević, Zorica
Article (Accepted Version)
Metadata
Show full item record
Abstract
Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.
Keywords:
Edaravone / amyotrophic lateral sclerosis (ALS) / ferroptosis / therapy / neurons / neurodegeneration
Source:
Current Drug Targets, 2020, 21, 8, 776-780
Publisher:
  • Bentham Science
Funding / projects:
  • Molecular mechanisms of redox signalling in homeostasis: adaptation and pathology (RS-173014)
Note:
  • This is the peer-reviewed version of the article: Spasic, Snezana; Nikolic-Kokic, Aleksandra; Miletic, Srdan; Orescanin-Dusic, Zorana; Spasic, Mihajlo B; Blagojevic, Dusko; Stevic, Zorica. Curr Drug Targets ; 21(8): 776-780, 2020, doi: https://doi.org/10.2174/1389450121666200220123305

DOI: 10.2174/1389450121666200220123305

ISSN: 1389-4501

WoS: 000542986600002

Scopus: 2-s2.0-85087096289
[ Google Scholar ]
8
5
URI
https://www.eurekaselect.com/179582/article
https://cer.ihtm.bg.ac.rs/handle/123456789/3966
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
IHTM
TY  - JOUR
AU  - Spasić, Snežana
AU  - Nikolić-Kokić, Aleksandra
AU  - Miletić, Srđan
AU  - Oreščanin-Dušić, Zorana
AU  - Spasić, Mihajlo
AU  - Blagojević, Duško
AU  - Stević, Zorica
PY  - 2020
UR  - https://www.eurekaselect.com/179582/article
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/3966
AB  - Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.
PB  - Bentham Science
T2  - Current Drug Targets
T1  - Edaravone May Prevent Ferroptosis in ALS
VL  - 21
IS  - 8
SP  - 776
EP  - 780
DO  - 10.2174/1389450121666200220123305
ER  - 
@article{
author = "Spasić, Snežana and Nikolić-Kokić, Aleksandra and Miletić, Srđan and Oreščanin-Dušić, Zorana and Spasić, Mihajlo and Blagojević, Duško and Stević, Zorica",
year = "2020",
abstract = "Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.",
publisher = "Bentham Science",
journal = "Current Drug Targets",
title = "Edaravone May Prevent Ferroptosis in ALS",
volume = "21",
number = "8",
pages = "776-780",
doi = "10.2174/1389450121666200220123305"
}
Spasić, S., Nikolić-Kokić, A., Miletić, S., Oreščanin-Dušić, Z., Spasić, M., Blagojević, D.,& Stević, Z.. (2020). Edaravone May Prevent Ferroptosis in ALS. in Current Drug Targets
Bentham Science., 21(8), 776-780.
https://doi.org/10.2174/1389450121666200220123305
Spasić S, Nikolić-Kokić A, Miletić S, Oreščanin-Dušić Z, Spasić M, Blagojević D, Stević Z. Edaravone May Prevent Ferroptosis in ALS. in Current Drug Targets. 2020;21(8):776-780.
doi:10.2174/1389450121666200220123305 .
Spasić, Snežana, Nikolić-Kokić, Aleksandra, Miletić, Srđan, Oreščanin-Dušić, Zorana, Spasić, Mihajlo, Blagojević, Duško, Stević, Zorica, "Edaravone May Prevent Ferroptosis in ALS" in Current Drug Targets, 21, no. 8 (2020):776-780,
https://doi.org/10.2174/1389450121666200220123305 . .

DSpace software copyright © 2002-2015  DuraSpace
About CeR – Central Repository | Send Feedback

re3dataOpenAIRERCUB
 

 

All of DSpaceInstitutions/communitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About CeR – Central Repository | Send Feedback

re3dataOpenAIRERCUB